Misra Veet 4

What Happened Misra Veet, CFO of Ascentage Pharma Group International (AAPG), received an award of 18,584 restricted stock units (RSUs) on April 20, 2026. The RSUs show an acquisition price of $0.00 on the Form 4 (derivative grant); they represent a contingent right to receive one ordinary share per RSU upon vesting. According to the filing, these RSUs vest immediately and have no expiration date.

Key Details

• Transaction date: 2026-04-20; Form 4 filed 2026-04-21 (appears timely).
• Transaction type/code: Award/Grant (A); reported as a derivative.
• Quantity and price: 18,584 RSUs @ $0.00.
• Shares owned after transaction: Not specified in the provided filing.
• Footnotes/remarks: F1 — each RSU converts to one ordinary share upon vesting; RSUs vest immediately and have no expiration. Form filed using a special power of attorney.

Context RSU grants are a form of compensation rather than an open-market purchase or sale. Because these RSUs vested immediately, they now represent a right to receive ordinary shares (subject to the issuer’s settlement procedures). Such awards are common for executives and are not, by themselves, a clear buy or sell signal for investors.